The Science

Precision Medical Management

Numerous clinical studies have documented that PGx testing leads to improved clinical outcomes and significant costs savings in the right patient populations.

 

5

Annual medical costs for certain patient populations may run as much as $5,188 more per year in the absence of PGx testing to determine optimal treatments compared to situations when pharmacogenetic data was applied (1)

5

PGx testing of complex chronic disease patients resulted in a reduction in hospitalization rates (9.8% vs. 16.1%), ED visits (4.4% vs. 15.4%) and overall healthcare resource utilization (49% vs. 72.2%) vs. Control (2)

5

PGx testing represents a promising strategy to reduce costs and utilization among patients with mood and anxiety disorders. six-month cost of care was $1,948 lower per individual in the tested group versus the control group (3)

5

PGx testing of complex chronic disease patients resulted in a reduction in hospitalization rates (9.8% vs. 16.1%), ED visits (4.4% vs. 15.4%) and overall healthcare resource utilization (49% vs. 72.2%) vs. Control (2)

Read More

For Payors

A turnkey pharmacogenomics risk management and medication optimization platform for employers, health plans, third-party administrators and other payors

The Study

Pharmacogenomic testing and case management for members with complex chronic disease.

Improving Clinical Outcomes

Read more about the people behind it all.

Resources

Privacy

Terms of Use

Copyright 2019 © Rx-Precision, Inc. All rights reserved.

The Science

Precision Medical Management

Numerous clinical studies have documented that PGx testing leads to improved clinical outcomes and significant costs savings in the right patient populations.

 

5

Annual medical costs for certain patient populations may run as much as $5,188 more per year in the absence of PGx testing to determine optimal treatments compared to situations when pharmacogenetic data was applied (1)

5

PGx testing of complex chronic disease patients resulted in a reduction in hospitalization rates (9.8% vs. 16.1%), ED visits (4.4% vs. 15.4%) and overall healthcare resource utilization (49% vs. 72.2%) vs. Control (2)

5

PGx testing represents a promising strategy to reduce costs and utilization among patients with mood and anxiety disorders. six-month cost of care was $1,948 lower per individual in the tested group versus the control group (3)

5

PGx testing of complex chronic disease patients resulted in a reduction in hospitalization rates (9.8% vs. 16.1%), ED visits (4.4% vs. 15.4%) and overall healthcare resource utilization (49% vs. 72.2%) vs. Control (2)

Read More

For Payors

A turnkey pharmacogenomics risk management and medication optimization platform for employers, health plans, third-party administrators and other payors

The Study

Pharmacogenomic testing and case management for members with complex chronic disease.

Improving Clinical Outcomes

Read more about the people behind it all.